Product name as reported
Propoxyphene Napsylate and Acetaminophen: adverse event reports filed with FDA
1,719 reports list it as a suspect or interacting product, 2004–2020.
- 1,719
- reports as suspect product
- 0% of all reports · about 77 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 97.9%
- marked serious by the reporter
- 57.4% across all reports
- 11.9%
- record death among outcomes, as reported
- 205 reports · not verified by FDA
Between February 2004 and December 2020, 1,719 adverse event reports received by FDA list the product name "Propoxyphene Napsylate and Acetaminophen" as reporters wrote it as a suspect or interacting product. Reports that mention it only as a concomitant medication (100) are left out of every figure here.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 77 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded cardiovascular disorder (82%), movement disorder (73.8%) and nervous system disorder (73.8%). A report can list several reactions, so shares add to more than 100%; 95 different terms appear across these reports. Cardiovascular disorder is recorded in 82% of these reports, against 0.1% of all reports in the database.
97.9% of the reports are marked serious by the reporter; 11.9% record death among the outcomes and 11.5% record hospitalisation, as reported. 91.6% of the reports came from other health professionals, and the largest patient age group is 45 to 64 (1.2%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
No report listing Propoxyphene Napsylate and Acetaminophen was received in the five years to June 2026; the latest was received in December 2020.
By year received
Reactions recorded in the reports
share of Propoxyphene Napsylate and Acetaminophen reports recording the termall reports in the database
- Cardiovascular disorder82%1,410
- Movement disorder73.8%1,268
- Nervous system disorder73.8%1,268
- Cardiac disorder15.5%266
- Deaththe patient died; cause not stated by this term8.3%142
- Arrhythmia4%69
- Myocardial infarctionheart attack2.2%38
- Tachycardiafast heart rate1.6%28
- Bradycardiaslow heart rate1.3%22
- Atrial fibrillationan irregular heart rhythm1.2%20
- Heart rate irregular0.9%16
- Palpitationsawareness of the heartbeat0.9%16
- Cardiac arrestthe heart stopped0.9%15
- Completed suicidedeath by suicide0.9%15
- Chest painchest pain0.7%12
- Dizzinesslight-headedness or unsteadiness0.6%11
- Electrocardiogram QT prolongeda QT prolongation on the ECG0.6%11
- Multiple drug overdose0.6%10
- Dyspnoeashortness of breath0.5%9
- Nauseafeeling sick0.5%9
- Syncopefainting0.5%9
- Ventricular tachycardiaa fast rhythm from the lower heart chambers0.5%8
- Multiple drug overdose intentional0.4%7
- Cerebrovascular accidentstroke0.3%6
- Respiratory arrestbreathing stopped0.3%6
- Astheniaweakness or lack of energy0.3%5
- Falla fall0.3%5
- Ventricular fibrillationa chaotic rhythm from the lower heart chambers0.3%5
Top 30 of 95 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Pain | 1,561 | 90.8% |
| Back pain | 4 | 0.2% |
| Pain management | 4 | 0.2% |
| Arthralgia | 3 | 0.2% |
| Abdominal pain | 2 | 0.1% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,719 reports.
In context
| Measure | Propoxyphene Napsylate and Acetaminophen | All reports |
|---|---|---|
| Reports as suspect product | 1,719 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 97.9% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 119 | 91 |
| Hospitalisation recorded, per 1,000 reports | 115 | 213 |
| Consumer-filed share | 4.5% | 45.8% |
| Top term, share of reports | Cardiovascular disorder 82% | 0.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Propoxyphene Napsylate and Acetaminophen reports
How many adverse event reports has FDA received for Propoxyphene Napsylate and Acetaminophen?
1,719 reports list Propoxyphene Napsylate and Acetaminophen as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 100 list it only as a concomitant medication.
What reactions are recorded in Propoxyphene Napsylate and Acetaminophen reports?
cardiovascular disorder (82%), movement disorder (73.8%), nervous system disorder (73.8%), cardiac disorder (15.5%) and death (8.3%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Propoxyphene Napsylate and Acetaminophen was responsible.
How serious are the reports?
97.9% are marked serious by the reporter. Among the outcomes recorded, 11.9% of reports include death and 11.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
lawyer (91.6%), consumer or non-health professional (4.5%) and physician (1.3%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Propoxyphene Napsylate and Acetaminophen rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Propoxyphene Napsylate and Acetaminophen was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Propoxyphene Napsylate and Acetaminophen?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Propoxyphene Napsylate and Acetaminophen as a suspect or interacting product; reports listing it only as a concomitant medication (100) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.